BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 24554304)

  • 1. Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome.
    Gauchan D; Shaaban H; Gedeon D; Maroules M
    Ann Hematol; 2014 Oct; 93(10):1777-8. PubMed ID: 24554304
    [No Abstract]   [Full Text] [Related]  

  • 2. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag.
    Scheinberg P; Singulane CC; Barbosa LS; Scheinberg M
    Clin Rheumatol; 2014 Sep; 33(9):1347-9. PubMed ID: 24740463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag for treatment of thrombocytopenia-associated disorders.
    Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
    Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag in thrombocytopenia.
    Lawson A
    N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18322290
    [No Abstract]   [Full Text] [Related]  

  • 8. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
    Violi F; Pignatelli P
    N Engl J Med; 2012 Nov; 367(21):2056. PubMed ID: 23171115
    [No Abstract]   [Full Text] [Related]  

  • 9. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
    Lisman T; Porte RJ
    N Engl J Med; 2012 Nov; 367(21):2055-6. PubMed ID: 23171114
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
    Modi Y; Shaaban H; Gauchan D; Maroules M
    J Oncol Pharm Pract; 2015 Feb; 21(1):74-5. PubMed ID: 25063763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eltrombopag reduces bleeding complications and the need of platelet transfusions in cirrhotic thrombocytopenic patients subjected to invasive procedures.
    Castelli R; Gidaro A; Lambertenghi Deliliers G
    Blood Coagul Fibrinolysis; 2021 Mar; 32(2):163-166. PubMed ID: 33555693
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecule of the month. Eltrombopag.
    Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome.
    Mavroudi I; Pyrovolaki K; Pavlaki K; Kozana A; Psyllaki M; Kalpadakis C; Pontikoglou C; Papadaki HA
    Leuk Res; 2011 Mar; 35(3):323-8. PubMed ID: 20688394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia.
    Trautmann K; Jakob C; von Grünhagen U; Schleyer E; Brümmendorf TH; Siegert G; Ehninger G; Platzbecker U
    Thromb Haemost; 2012 Aug; 108(2):397-8. PubMed ID: 22739569
    [No Abstract]   [Full Text] [Related]  

  • 15. Usage of eltrombopag for chronic immune thrombocytopenia as a pretreatment for splenectomy.
    Uwagawa T; Misawa T; Furukawa K; Ito R; Futagawa Y; Yahagi Y; Aiba K; Yanaga K
    Acta Haematol; 2013; 129(1):45-7. PubMed ID: 23128016
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
    Will B; Kawahara M; Luciano JP; Bruns I; Parekh S; Erickson-Miller CL; Aivado MA; Verma A; Steidl U
    Blood; 2009 Oct; 114(18):3899-908. PubMed ID: 19710504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
    Comont T; Meunier M; Cherait A; Santana C; Cluzeau T; Slama B; Laribi K; Giraud JT; Dimicoli S; Berceanu A; Le Clech L; Cony-Makhoul P; Gruson B; Torregrosa J; Sanhes L; Jachiet V; Azerad MA; Al Jijakli A; Gyan E; Gaudin C; Broner J; Guerveno C; Guillaume T; Ades PL; Beyne-Rauzy O; Fenaux P;
    Br J Haematol; 2021 Jul; 194(2):336-343. PubMed ID: 34151423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C: two case reports].
    Guglieri-López B; Ventura-Cerdá JM; Carmena-Carmena J; Climente-Mónica M
    Farm Hosp; 2013; 37(5):419-21. PubMed ID: 24128106
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune thrombocytopenic purpura--from agony to agonist.
    Schwartz RS
    N Engl J Med; 2007 Nov; 357(22):2299-301. PubMed ID: 18046034
    [No Abstract]   [Full Text] [Related]  

  • 20. Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
    Imbach P; Crowther M
    N Engl J Med; 2011 Aug; 365(8):734-41. PubMed ID: 21864167
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.